India, July 23 -- Prostatype Genomics AB (publ) (PGO0.F), Wednesday announced interim report for the first half of the fiscal year 2025.
During this period, the company reported net sales of 246 TSEK, compared to 115 TSEK last year.
Loss amounted to 23,920 TSEK or 0.65 SEK per share, compared to a loss of 19,665 TSEK or 19.85 SEK per share in the previous year.
Looking forward, CEO Fredrik Rickman expects an approval of the company's Medicare application this autumn after an active dialogue in a positive spirit with Medicare during the period.
Currently, Prostatype's stock is trading at 0.0750 euros, up 5.63 percent on the Frankfurt.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with...